However, when treatment with agonist antibodies targeting OX40 or CD137 individually were compared with FS120m in a CT26 tumor model, it was found that only FS120m was capable of inducing profound antitumor activity (45), indicating that it is only through targeting both pathways simultaneously that tumor regression can be achieved. The gene discussed is TNFRSF4; the disease is neoplasm.